Skip to content
Search
Facebook
 
ADCSADCS
ADCS
Alzheimer's Disease Cooperative Study
  • About Us
    • About ADCS
    • Meet the Directors
    • ADCS Cores
    • ADCS Clinical Trials Network
    • Steering Committee Voting Members
  • Public & Participant Resources
    • About Alzheimer’s Disease
    • AD Resources
    • Clinical Sites
    • Types of Studies
    • Clinical Trials
    • Lifestyle Interventions
    • Alzheimer’s Study Quilt Project
  • Investigator Resources
    • Publications
    • Study Resources
    • Data Sharing
    • Biospecimen Bank
    • ADCS Instruments
    • Preliminary Proposals
    • Combination Therapy Call OPEN
  • CTMS
    • Clinical Conductor Enterprise
    • Clinical Conductor Site Portals
  • Donate
  • Steering Committee Members
  • Staff Resources
  • About Us
    • About ADCS
    • Meet the Directors
    • ADCS Cores
    • ADCS Clinical Trials Network
    • Steering Committee Voting Members
  • Public & Participant Resources
    • About Alzheimer’s Disease
    • AD Resources
    • Clinical Sites
    • Types of Studies
    • Clinical Trials
    • Lifestyle Interventions
    • Alzheimer’s Study Quilt Project
  • Investigator Resources
    • Publications
    • Study Resources
    • Data Sharing
    • Biospecimen Bank
    • ADCS Instruments
    • Preliminary Proposals
    • Combination Therapy Call OPEN
  • CTMS
    • Clinical Conductor Enterprise
    • Clinical Conductor Site Portals
  • Donate
  • Steering Committee Members
  • Staff Resources

ADCS Director Howard Feldman, MD talks about the T2 Protect trial and a bright future for Alzheimer’s research

You are here:
  1. Home
  2. Research News
  3. ADCS Director Howard Feldman, MD…

Post navigation

PreviousPrevious post:Newly discovered Alzheimer’s genes lead to hope for future treatmentsNextNext post:2018 Alzheimer’s Association Facts & Figures Released
ADCS Research News
  • Home Based Assessments Trial Primary Paper in the Journal of Alzheimer’s & Dementia
  • “Young Latino’s Working in Alzheimer’s” Airs Tonight on UCSD TV and is Streaming on the Brain Channel
  • 40 Sites Across The Country To Test New Alzheimer’s Drug
  • Newly discovered Alzheimer’s genes lead to hope for future treatments
  • ADCS Director Howard Feldman, MD talks about the T2 Protect trial and a bright future for Alzheimer’s research
About ADCS
The Alzheimer’s Disease Cooperative Study (ADCS) was formed in 1991 as a cooperative agreement between the National Institute on Aging (NIA) and the University of California San Diego.
Contact Us
  • E-mail:
    alzinfo@ucsd.edu
  • Phone:
    858-246-1333

Find us on:

FacebookRssMail
Location
Shipping Address:
9452 Medical Center Drive
4th Floor
La Jolla, CA 92037

Mailing Address:
9500 Gilman Dr
MC0949
La Jolla, CA 92093-0949
Copyright 2017 Regents of the University of California.